Intec Pharma Operating Income

The latest operating income for NTEC is $-14M as of March 2021. That compares with $-26M in the prior-year period — up 46.1% year over year. Investors often review this figure alongside Intec Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, NTEC's operating income moved from $-26M to $-14M — a 46.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Intec Pharma's operating scale or balance-sheet position.

A operating income figure of $-14M for NTEC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NTEC's operating income ($-14M), review year-over-year change from $-26M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Intec Pharma's operating income against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.